SHIRE VIROPHARMA INC has a total of 81 patent applications. It increased the IP activity by 12.0%. Its first patent ever was published in 2005. It filed its patents most often in United States, Japan and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are PVP LABS PTE LTD, SCICLONE PHARMACEUTICALS INT LTD and IMMUNOFRONTIER INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 21 | |
#2 | Japan | 10 | |
#3 | EPO (European Patent Office) | 8 | |
#4 | Canada | 4 | |
#5 | Hungary | 4 | |
#6 | Israel | 4 | |
#7 | Montenegro | 4 | |
#8 | Serbia | 4 | |
#9 | Brazil | 3 | |
#10 | China | 3 | |
#11 | Republic of Korea | 3 | |
#12 | Mexico | 3 | |
#13 | Singapore | 3 | |
#14 | South Africa | 3 | |
#15 | Hong Kong | 2 | |
#16 | Australia | 1 | |
#17 | United Kingdom | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry | |
#4 | Measurement | |
#5 | Control |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Analysing materials | |
#5 | Teaching materials | |
#6 | Sugars | |
#7 | Acyclic or carbocyclic compounds | |
#8 | Organic chemistry methods |
# | Name | Total Patents |
---|---|---|
#1 | Manning Mark Cornell | 27 |
#2 | Ruddy Stephen | 19 |
#3 | Gallagher Cynthia | 19 |
#4 | Broom Colin | 16 |
#5 | Mark Cornell Manning | 13 |
#6 | Cynthia Gallagher | 13 |
#7 | Uknis Marc E | 11 |
#8 | Steven Ruddy | 9 |
#9 | Holcomb Ryan Erik | 9 |
#10 | Ruddy Steven | 9 |
Publication | Filing date | Title |
---|---|---|
US2016175338A1 | Maribavir isomers, compositions, methods of making and methods of using | |
HUE041809T2 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor | |
US2015132296A1 | Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders | |
KR20210021146A | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency |